COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies

Manuela Di Fusco, Jay Lin, Shailja Vaghela, Melissa Lingohr-Smith, Jennifer L Nguyen, Thomas Scassellati Sforzolini, Jennifer Judy, Alejandro Cane, Mary M Moran
doi: https://doi.org/10.1101/2021.12.29.21268511

Article Information

doi 
https://doi.org/10.1101/2021.12.29.21268511
History 
  • December 31, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Manuela Di Fusco1,*,
  2. Jay Lin2,
  3. Shailja Vaghela3,
  4. Melissa Lingohr-Smith2,
  5. Jennifer L Nguyen1,
  6. Thomas Scassellati Sforzolini1,
  7. Jennifer Judy1,
  8. Alejandro Cane1 and
  9. Mary M Moran4
  1. 1Pfizer Inc., New York, NY USA
  2. 2Novosys Health, Green Brook, NJ, USA
  3. 3HealthEcon Consulting Inc. ON, Canada
  4. 4Pfizer Inc., Collegeville, PA, USA
  1. ↵*Corresponding author:
    Manuela Di Fusco, Patient and Health Impact, Health Economics and Outcomes Research, Pfizer, Inc., 235 East 42nd St., New York, NY USA 10017, Manuela.difusco{at}pfizer.com, Phone: 718-288-1620
Back to top
Posted December 31, 2021.
Download PDF
Data/Code
Email
COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies
Manuela Di Fusco, Jay Lin, Shailja Vaghela, Melissa Lingohr-Smith, Jennifer L Nguyen, Thomas Scassellati Sforzolini, Jennifer Judy, Alejandro Cane, Mary M Moran
medRxiv 2021.12.29.21268511; doi: https://doi.org/10.1101/2021.12.29.21268511
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area